BurkholderiaInfections Market - Global Industry Insights, Trends, Outlook, and OpportunityAnalysis, 2018-2026
Burkholderia infections arecaused by Burkholderia cepacia. It is a gram negative bacillus found in aquaticenvironment. It is a low virulent bacteria and is a frequent colonizer offluids used in the hospitals such as IV fluid, irrigation solution etc. B.cepacia can cause health problems to some people such as patients sufferingfrom weakened immune system or chronic lung diseases. Burkholderia infectionsymptom can vary widely in people, ranging from no symptoms to seriousrespiratory infection. Based on recent genomic subtyping techniques, Burkholderiainfection can be transmitted from person to person. Patients with lung disease such as asthma,CFTR, and COPD are at high risk of suffering from Burkholderia infection.Burkholderia cepacia is resistant to multiple antibiotic such as aminoglycosides,antipseudomonal third-generation cephalosporins and antipseudomonalpenicillins.
Increasing prevalence of lungdiseases is expected to fuel growth of the Burkholderia infections market. Theexact cause for asthma, cystic fibrosis is unknown, though the risk factors canbe transferred generation from generation. As per the report of British LungFoundation, in 2011, an estimated 1.2 million people are living with chronicobstructive pulmonary disease (COPD) and has grown by 27% in the last decade inthe U.K. According to the U.S. Cystic Fibrosis Foundation, Europe accounted forthe highest number of reported cases of cystic fibrosis in 2012. The growingcases of COPD, asthma and other lung diseases create high risk of burkholderiainfection creating an opportunity for manufacturers. Burkholderia infectionsalso cause complications such as soft tissue infections, urinary tractinfection and surgical wound infections. It creates an opportunity for themanufacturers to focus on overall treatment. The increasing outbreaks ofburkholderia infection has created focus towards the need for proper treatmentprocedure.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/153
Many organization and governmentpolicies have included burkholderia infection as one of the severe infectionsspread from healthcare facilities. Transmission of B. cepacia from contaminatedmedicines and medical devices. In 2005, CDC notified several states cluster ofpneumonia and other infection caused by B. cepacia associated with contaminatedmouthwash. In October, 2016, Nurse Assist Inc, recalled its normal saline flushIV syringes due to Burkholderia Cepacia bloodstream infection. FDA identifiedthis as Class I recall, one of the most serious types of recall which may causeserious injuries or death. In 2004, Burkholderia Cepacia was linked tonosocomial infection among Intensive Care Unit patient and was associated withexposure to sublingual probes. The growing concerns related to contaminatedmedicines and medical devices are expected to create opportunity for productmanufacturers in the burkholderia infections market. The effect of B. cepaciaon people varies person to person which leaves the infection with no specifictreatment. The unavailability of proper treatment creates hindrance to theoverall market. North America is expected to account for maximum share of theglobal burkholderia infections market, owing to the better diagnosticfacilities, increasing awareness and government initiative for early diagnosisand treatment of burkholderia infection. Europe is expected to be the secondmost lucrative burkholderia infections market.
Burkholderia Infections Market isHighly Fragmented
The market is highly fragmenteddue to the presence of many emerging players. Major players involved in theburkholderia infections market includes Novabiotics Ltd, iQur Ltd, AridisPharmaceuticals LLC, NanoBio Corporation, SUN pharma and others.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/burkholderia-infections-market-153
Key Developments
Continuous research anddevelopment activities are expected to facilitate growth of the burkholderiainfections market. For instance, in February 2019, the National Institutes ofHealth (NIH) awarded a US$ 3.34 million grant to researchers at Case WesternReserve University School of Medicine to research and develop a technique forsensitizing Burkholderia multivorans, a common pathogen found in patients withlung diseases, to antibiotics.
Increasing number of investmentsby regulatory authorities, as well as private organisations to fund R&Dactivities is driving the market growth. In August 2019, the BiomedicalAdvanced Research and Development Authority (BARDA), announced a 2-year grantof up to US $20.7 million to VenatoRx Pharmaceuticals, who will thencollaborate with BARDA’s Office of the Assistant Secretary for Preparedness andResponse (ASPR), and the Department of Defense’s Defense Threat ReductionAgency (DTRA) to test the efficacy of VNRX-5133 compound in treating pathogens,specifically, melioidosis-causing bacterium Burkholderia pseudomallei.
Moreover, in October 2018,Synspira’s candidate therapy, SNSP113, received the orphan drug status from theU.S. Food and Drug Administration (FDA) for treating bacterial infections suchas Burkholderia and non-tuberculous Mycobacteria in patients with cysticfibrosis (CF).
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/153
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
